Disability, fatigue, depression, cognitive impairment, and unemployment are primary risk factors for a poor quality of life in people with multiple sclerosis (MS), according to a recent review study. Conversely, higher self-esteem, self-efficacy, resilience, and social support were identified as protective factors for quality of life (QoL).
Surf & Turf Therapy, a nonprofit organization that aims to improve the quality of life of those with disabilities through non-conventional therapeutic activities, has launched a donation drive to help the organization extend its services to more people. The nonprofit led by Jillian Stewart, a licensed physical therapist,…
The expansion of chronic white matter lesions in people with relapsing-remitting multiple sclerosis (RRMS) determined the increase in total lesion volume and significantly contributed to disease progression, a study has revealed. The study, “Expansion of chronic…
Nasal delivery of Rebif’s active ingredient interferon-beta, loaded in carbohydrate-based nanoparticles, reduced disease progression and nerve cell inflammation in a preclinical mouse model of multiple sclerosis (MS), a study demonstrated. This alternate, non-invasive, low-cost treatment strategy…
Studied for the first time, Aubagio (teriflunomide) slowed the loss of cortical grey matter and whole-brain volume in people with clinically isolated syndrome (CIS) during two years of therapy, a study found. The treatment was especially effective in those without brain lesions before treatment.
Tecfidera (dimethyl fumarate) may be an effective treatment option for patients with early relapsing forms of multiple sclerosis (MS) who fail to respond adequately to glatiramer acetate, according to a post-hoc analysis of an observational study. The findings were reported in an article, “Effectiveness…
Motor rehabilitation using virtual reality (VR) may improve hand and arm function in people with multiple sclerosis (MS), according to a review study. Evidence of its beneficial effect is, however, still preliminary, as most analyzed studies included small patient groups and some failed to show statistically significant improvements in upper…
People with multiple sclerosis (MS) are at a higher risk of developing and dying from bladder cancer than people without the neurodegenerative disorder, according to a Canadian population-based study. However, no differences were found between MS patients and unaffected individuals in terms of their risk of breast and…
Women who have never given birth are more likely to develop early onset of progressive multiple sclerosis, according to a new study, which also found that a woman’s number of pregnancies showed a positive effect in delaying the disease. In addition, entering menopause earlier, before the age of 46,…
Novartis has partnered with iHeartRadio to launch the first free on-demand streaming radio station dedicated to the multiple sclerosis (MS) community. Named MS Vibes, the station is focused “on popular music, educational content and relatable topics to which listeners can connect, uplift and recharge,” Leverne Marsh, vice president and…
A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient populations. The initiative seeks to extend the reach of clinical studies to underserved populations in the nation’s urban and rural…
People with multiple sclerosis (MS) may have cognitive defects that cannot be detected using conventional paper-and-pen tests but that can be assessed with computer-based tests, a new study shows. The findings also indicate that people with MS may be more susceptible to cognitive impairment when the brain has to address increased…
A particular type of gut microbiota-reactive immune cells, called IgA-producing B-cells, travels to the brain of multiple sclerosis (MS) patients during relapses, where they produce anti-inflammatory molecules, a study shows. The underlying mechanisms of this event and these cells’ role in MS remain largely unclear, but these…
Lower levels of pro-inflammatory immune signaling proteins were found in the blood of people with relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri (natalizumab) and were associated with fewer relapses and less disability, a study has found.
Tecfidera (dimethyl fumarate) was detected in the breast milk of two women using the oral therapy to treat their multiple sclerosis, but at concentrations well below the “theoretical threshold of concern” for an infant, a case study reported. According to its investigators, this is the first…
An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities. Patients reliant on wheelchairs or aids to walk even short distances generally have…
Early and continuous use of Ocrevus (ocrelizumab) significantly slows disability progression and delays the time until wheelchair reliance in people with primary progressive multiple sclerosis (PPMS), new Phase 3 data spanning more than six years show. Findings from the ORATORIO trial, comparing immediate use with a two-year delay, support Ocrevus’ sustained…
Typing patterns in daily smartphone use show clinically relevant changes over time in people with multiple sclerosis (MS), but not among healthy individuals, a study shows. Notably, these variations often coincided with clinically meaningful changes in measures of disease activity, disability, and/or fatigue in MS patients with and without…
Patients in the early stages of multiple sclerosis with mild to moderate symptoms of depression performed worse on cognitive tests related to multitasking than on those focused on single tasks, a study has found. Notably, no such association was observed among healthy individuals, suggesting an MS-related link between mood,…
The nonprofit Autoimmune Registry (ARI) has published its first comprehensive list of autoimmune diseases, with information addressing more than 150 disorders, their subtypes, and prevalence in the U.S. This list was created in part to provide patients and scientists easy access to the latest peer-reviewed research, information on clinical…
Progressive multiple sclerosis (MS) is the focus of the 2020 virtual European Multiple Sclerosis Platform (EMSP) annual meeting that runs though Friday, Nov. 20. Registration is free for the two-day conference. Those interested in participating can register here. According to a EMSP press release, topics to be discussed include the most…
A software platform, called CogniSoft, allows for automated assessments of cognitive health in people with multiple sclerosis (MS). The platform was described in the study “CogniSoft: A Platform for the Automation of Cognitive Assessment and Rehabilitation of Multiple Sclerosis,” published in the journal Computers. Cognitive impairment…
Marked differences in disease characteristics are observed between male and female patients with multiple sclerosis (MS) but they are more pronounced when comparing patients across clinical subtypes, a new study finds. The analysis found that although women are more prone to…
Using a small molecule called TEPP-46 to block the non-metabolic function of the enzyme pyruvate kinase M2 (PKM2) in T-helper (Th) immune cells did not lessen disease severity and redirected inflammation and neural damage from the spinal cord to the brain in a mouse model of multiple sclerosis…
Scientists have created myelin-producing cells, called oligodendrocytes, from pluripotent stem cells derived from patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) in just three weeks. They also demonstrated these lab-made oligodendrocytes were able to produce myelin — the fatty substance that normally wraps around neurons’…
The U.K.’s MS Trust has been awarded £50,000 (about $65,800) from the Coronavirus Community Support Fund — distributed by The National Lottery Community Fund — to further its “Supporting the MS community during Covid-19” project. Expected to run for six months, the project aims…
Note: This story was updated Aug. 17, 2021, to note that T.gondii infection is a risk factor for rheumatoid arthritis and lupus, not a protective factor. Toxoplasmosis, an infection by the parasite Toxoplasma gondii, may confer a certain level of protection against multiple sclerosis (MS), according…
Start2Cure Foundation is funding a research project that will investigate the potential of a gene therapy approach to treat multiple sclerosis (MS). MS is an autoimmune disease characterized by the damage and loss of myelin — the protective layer around nerve fibers, or axons, that is crucial to the…
A bone marrow transplant may be particularly useful for those with relapsing forms of multiple sclerosis (MS) who, despite treatment with high-efficacy disease-modifying therapies (DMTs), continue to experience relapses or show signs of new lesions, experts say. According to new recommendations from the National Multiple Sclerosis Society,…
The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating event associated with multiple sclerosis (MS) can predict brain atrophy up to a decade later, a new study shows. Titled “Association of Serum Neurofilament Light Levels…
Get regular updates to your inbox.
